| Atypical HUS |
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry |
Open to enrollment |
PI: Elaine Majerus
Contact: Vanetta Worthy
worthyv@wustl.edu
314-362-9998 |
Atypical HUS |
| Autoimmune Hemolytic Anemia |
A Phase 2 Study of INCB050465 in Participants with Autoimmune Hemolytic Anemia |
Open |
PI: Morey Blinder
Contact: Ashley Simpson
ashley.simpson@wustl.edu
314-286-1550 |
|
| Banking Laboratory Studies |
Blood Acquistion for Investigation of Thrombotic Disorders |
Open |
PI: Elaine Majerus
Contact: Lisa Garrett
garrett_l@wustl.edu
314-362-9998 |
Thrombosis Banking |
| Bleeding and clotting disorders |
CDC Community Counts: Surveillance Project for Patients with Bleeding and Blood Clotting Disorders |
Open |
PI: Elaine Majerus
Contact: Bill Berger
bergerwb@wustl.edu
314-362-9996 |
|
| Blood Clots in Cancer Patients |
Direct Oral Anticoagulants vs. Low Molecular Weight Heparin +/- Warfarin for Venous Thromboemboli in Cancer Patients (CANVAS) |
Open
 |
PI: Kristen Sanfilippo
Contact: Andrew Maus
amaus@wustl.edu
314-747-7813 |
|
| Blood Clots in Cancer Patients |
A Phase 3 Study Evaluating Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis (ACCRU-SC-1601) |
Open
|
PI: Kristen Sanfilippo
Contact: Andrew Maus
amaus@wustl.edu
314-747-7813 |
|
| CNL/aCML |
Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia |
Ongoing; closed to enrollment |
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 |
|
| Hemophilia A |
A Phase 3 Study of Valoctocogene Roxaparvovec in Hemophilia A Patients |
Open |
PI: Elaine Majerus
Contact: Ashley Simpson
ashley.simpson@wustl.edu
314-286-1550 |
Male patients only |
| Hemophilia A |
A Phase 3 Study of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg |
Open |
PI: Elaine Majerus
Contact: Ashley Simpson
ashley.simpson@wustl.edu
314-286-1550 |
Male patients only |
| Hemophilia/Bleeding |
American Thrombosis and Hemostasis Network Data Collection |
Open |
PI: Elaine Majerus
Contact: Bill Berger
bergerwb@wustl.edu
314-362-9996 |
|
| Myelodysplastic Syndrome |
A Phase 3 Study of Roxadustat for Anemia in MDS patients |
Open to enrollment
|
PI: Amy Zhou
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 |
|
| Myelofibrosis |
A Phase 2 Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis |
Open and enrolling
|
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 |
MF patients with suboptimal response to ruxolitinib |
| Myelofibrosis |
A Phase 2 Study of Pacritinib in Myelofibrosis Patients Previously Treated with Ruxolitinib |
Suspended to enrollment
|
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 |
Prior ruxolitinib treatment failure/intolerance and palpable splenomegaly |
| Myelofibrosis |
Extended Access of Momelotinib in Adults with Myelofibrosis (352-4365) |
Enrolling by invitation only
|
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 |
|
| Myelofibrosis |
Pevondistat in Combination with Ruxolitinib in Myelofibrosis Patients |
Open to enrollment
|
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 |
|
| Myelofibrosis |
A Phase 2 Dose Expansion Study of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis (MANIFEST) |
Open
|
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 |
|
| Myelofibrosis |
Phase 2 Study of KRT-232 in Myelofibrosis Patients Who Failed Prior JAK Inhibitor |
Open to enrollment
|
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 |
|
| Myelofibrosis |
Phase 3 Study of Fedratinib in Myelofibrosis Patients Previously Treated with Ruxolitinib |
Open
|
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-747-7960 |
|
| Myelofibrosis and Essential Thrombocythemia |
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) |
Ongoing; closed to enrollment
|
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 |
|
| Myeloid/Lymphoid Neoplasms |
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement |
Open
|
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 |
Patients with 8p11 (FGFR1) rearrangement |
| PNH |
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry |
Open to enrollment |
PI: Elaine Majerus
Contact: Vanetta Worthy
worthyv@wustl.edu
314-362-9998 |
PNH Registry |
| Polycythemia Vera |
Phase 2 Study of KRT-232 Vs. Ruxolitinib in Phlebotomy-Dependent Polycythemia Vera Patients |
Open
|
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 |
|
| Sickle Cell Disease |
A Phase II Trial of Regadenoson in Sickle Cell Anemia |
Open to enrollment |
PI: Elaine Majerus
Contact: Lisa Garrett
garrett_l@wustl.edu
314-362-0156 |
HbSS and S Beta Null |
| Sickle Cell Disease |
Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD) |
Ongoing; closed to enrollment |
PI: Elaine Majerus
Contact: Lisa Garrett
garrett_l@wustl.edu
314-362-0156 |
Hb SS and S Beta Null |
| Sickle Cell Disease |
A Phase 3 Study of GBTT440 Administered Orally to Patients with Sickle Cell Disease, GBT_HOPE |
Enrollment on hold |
PI: Morey Blinder
Contact: Ashley Simpson
ashley.simpson@wustl.edu
314-286-1550 |
|
| Systemic Mastocytosis |
A Phase 2 study of Avapritinib in Patients with Advanced Systemic Mastocytosis (BLU-285-2202) |
Pending
|
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 |
|
| Thrombocytopenia |
Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure |
Open |
PI: Morey Blinder
Contact: Ashley Simpson
ashley.simpson@wustl.edu
314-286-1550 |
|
to view the protocol (WUSTL key password required).
